Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Medtronic
Dow
Mallinckrodt

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 4,906,734

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 4,906,734
Title: Human conglutinin
Abstract:Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described. Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.
Inventor(s): Jensenius; Jens C. (Odense, DK)
Assignee: Novo Industri A/S (DK)
Application Number:06/939,112
Patent Claims:1. Human conglutinin in substantially pure form comprising a plasma protein of monomeric molecular weight of 40,000 daltons in the unreduced state and 66,000 daltons in the reduced state, and a polymeric relative molecular weight of 330,000 daltons in the unreduced state, said protein comprising in the monomeric reduced state the following amino acid composition:

said protein exhibiting calcium-dependent and sugar-inhiitable binding to complement-reacted immune complexes and zymosan, said protein being sensitive to collagenase digestion, and said protein cross-reacting with chicken and rabbit anti-bovine conglutinin antibody.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark5704/85Dec 10, 1985

Details for Patent 4,906,734

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Novo Industri A/S (DK) 2007-03-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Johnson and Johnson
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.